S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:TGTX

TG Therapeutics Short Interest Ratio and Short Volume

$49.62
-1.57 (-3.07 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.56
Now: $49.62
$51.54
50-Day Range
$27.13
MA: $45.61
$54.90
52-Week Range
$6.34
Now: $49.62
$56.74
Volume1.80 million shs
Average Volume1.81 million shs
Market Capitalization$6.52 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.24

Short Interest

TG Therapeutics (NASDAQ:TGTX) Short Interest Data

Current Short Volume:13,860,000 shares
Previous Short Volume:12,860,000 shares
Change Vs. Previous Month:+7.78%
Dollar Volume Sold Short:$217.74 million
Short Interest Ratio / Days to Cover:6.0
Last Record Date:January, 31 2020
Outstanding Shares:90,840,000 shares
Float Size:86,080,000 shares
Short Percent of Float:16.10%
Today's Trading Volume:1,802,685 shares
Average Trading Volume:1,806,920 shares
Today's Volume Vs. Average:-0.23%



TG Therapeutics (NASDAQ:TGTX) Short Interest History

DateShares Sold ShortDollar Volume Sold ShortPercentage ChangePercentage FloatDays to CoverPrice on Record Date
1/31/202013,860,000 $217.74 million 7.8%16.1%6.4$15.71
1/15/202013,860,000 $217.74 million 7.8%16.1%6.4$15.71
12/31/201912,860,000 $173.61 million 0.9%14.9%6.6$13.50

TG Therapeutics (NASDAQ:TGTX) Short Interest FAQ

speech bubbles
speech bubbles











What is TG Therapeutics' current short interest?

Short interest is the volume of TG Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 13,860,000 shares of TGTX short. 16.10% of TG Therapeutics' shares are currently sold short. View details.

What is a good short interest ratio for TG Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TG Therapeutics currently has a short interest ratio of 6.0.

What is a good short interest percentage for TG Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.10% of TG Therapeutics' floating shares are currently sold short.

Is TG Therapeutics' short interest increasing or decreasing?

TG Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 13,860,000 shares, an increase of 7.8% from the previous total of 12,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is TG Therapeutics' float size?

TG Therapeutics currently has issued a total of 131,490,000 shares. Some of TG Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TG Therapeutics currently has a public float of 86,080,000 shares.

How does TG Therapeutics' short interest compare to its competitors?

16.10% of TG Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to TG Therapeutics: Shiseido Company, Limited (0.00%), MERCK Kommanditgesellschaft auf Aktien (0.00%), UCB SA (0.00%), Alnylam Pharmaceuticals, Inc. (4.52%), Catalent, Inc. (0.00%), Horizon Therapeutics Public Limited (4.08%), BioMarin Pharmaceutical Inc. (4.89%), Ono Pharmaceutical Co., Ltd. (0.00%), Elanco Animal Health Incorporated (0.00%), and Grifols, S.A. (0.62%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Tesla, Inc. ($17.72 billion), Netflix, Inc. ($7.24 billion), Charter Communications, Inc. ($4.67 billion), Microchip Technology Incorporated ($3.34 billion), The Charles Schwab Co. ($2.53 billion), Match Group, Inc. ($2.07 billion), Carvana Co. ($1.86 billion), Omnicom Group Inc. ($1.86 billion), Snap Inc. ($1.75 billion), and Zillow Group, Inc. ($1.75 billion). View all of the most shorted stocks.

What does it mean to sell short TG Therapeutics stock?

Short selling TGTX is an investing strategy that aims to generate trading profit from TG Therapeutics as its price is falling. TG Therapeutics' stock is trading down $1.57 today. To short TG Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that TG Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against TG Therapeutics?

A short squeeze for TG Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TGTX, which in turn drives the price of the stock up even further.

How often is TG Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TGTX, twice per month. The most recent reporting period available is January, 31 2020.


This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.